Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Starpharma Holdings Limited ( (AU:SPL) ) has provided an announcement.
Starpharma Holdings Limited announced a change in the director’s interest, specifically the issuance of 6,525,939 Performance Rights to CEO Cheryl Maley under the SPL Performance Rights Plan. This move, approved by shareholders at the 2024 AGM, increases Maley’s total Performance Rights to 13,487,573, reflecting the company’s commitment to aligning executive incentives with shareholder interests.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
More about Starpharma Holdings Limited
Starpharma Holdings Limited operates in the pharmaceutical industry, focusing on the development of innovative products based on its proprietary dendrimer technology. The company is known for its work in drug delivery and pharmaceutical applications, aiming to enhance the efficacy and safety of various therapeutic agents.
Average Trading Volume: 1,334,682
Technical Sentiment Signal: Hold
Current Market Cap: A$152.7M
See more data about SPL stock on TipRanks’ Stock Analysis page.